Sato Y, Murata M, Sasahara J, Hayashi S, Ishii K, Mitsuda N
Department of Maternal Fetal Medicine, Osaka Prefectural Hospital Organization, Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka, Japan.
J Perinatol. 2014 Dec;34(12):945-7. doi: 10.1038/jp.2014.163.
Prenatal ultrasonography of a pregnant woman with a past history of total thyroidectomy for Graves' disease detected fetal tachycardia, fetal growth restriction and oligohydramnios at 30 weeks gestation. Because a high titer of thyroid-stimulating hormone receptor antibody was noted in maternal serum and the fetal goiter was detected on ultrasonography, fetal hyperthyroidism was strongly suspected and subsequently confirmed with cordocentesis at 31 weeks gestation. After treatment of fetal hyperthyroidism through oral maternal administration of methimazole (MMI) starting at 33 weeks gestation, fetal heart rate and amniotic fluid volume returned to normal ranges. Complete resolution of the fetal goiter was observed at 35 weeks gestation. A male infant was born at 35 weeks 6 days gestation via cesarean section in the absence of thyrotoxic findings; however, cord blood chemical analysis at birth indicated iatrogenic fetal hypothyroidism. In the present report, maternal therapy using MMI to resolve symptoms of fetal thyrotoxicosis, including fetal tachycardia and oligohydramnios, was successfully conducted.
一名有格雷夫斯病全甲状腺切除术病史的孕妇,在妊娠30周时进行产前超声检查,发现胎儿心动过速、胎儿生长受限和羊水过少。由于母体血清中甲状腺刺激素受体抗体滴度高,且超声检查发现胎儿甲状腺肿,强烈怀疑胎儿甲状腺功能亢进,随后在妊娠31周时通过脐血穿刺得以证实。从妊娠33周开始通过母体口服甲巯咪唑(MMI)治疗胎儿甲状腺功能亢进后,胎儿心率和羊水量恢复到正常范围。在妊娠35周时观察到胎儿甲状腺肿完全消退。一名男婴在妊娠35周6天时通过剖宫产出生,未出现甲状腺毒症表现;然而,出生时脐带血化学分析显示医源性胎儿甲状腺功能减退。在本报告中,成功地采用MMI进行母体治疗以缓解胎儿甲状腺毒症症状,包括胎儿心动过速和羊水过少。